The Pulmonary Fibrosis Foundation plans to expand its U.S. Care Center Network from the existing 45 facilities, which provide diagnosis and treatment. The network started with nine sites when it was launched in 2013. The foundation wants to see enough centers so 90 percent of patients in urban areas…
Pulmonary Fibrosis Foundation to Expand Its US Care Center Network
For the general population, it is widely known — via literature, social media, and personal experiences shared from others — that stress is not good for our health. It can have all kinds of implications for our bodies and minds that manifest in different ways. As a physical…
Although it’s changing in today’s society, it was previously presumed that someone with a disability was completely dependent on others. It’s quite common for people to think that because someone has a disability, they’re unable to complete daily tasks on their own. It’s this type of thinking that cultivates dependence…
Researchers identified a molecular pathway called ER stress, and a molecular factor known as PI3K, as promoters of pulmonary fibrosis in mice. This research suggests that PI3K and ER stress inhibitors are potential therapeutic options for pulmonary fibrosis. The study reporting the findings, “Involvement of ER stress, PI3K/AKT activation,…
https://www.youtube.com/watch?v=16Wn8GgOeU4 This video from the British Lung Foundation emphasizes the importance of keeping active if you have a chronic lung condition. MORE: Find out about the diagnostic tools needed for pulmonary fibrosis Pulmonary rehabilitation is recommended for most people who suffer from severe lung diseases such as pulmonary fibrosis.
Health Canada has issued a safety warning on Boehringer Ingelheim’s idiopathic pulmonary fibrosis therapy Ofev (nintedanib) after patients in a number of countries developed liver injuries and one died. IPF patients should stop taking Ofev and seek medical assistance if they develop signs of liver damage, Canadian officials said. Those…
For patients living with idiopathic pulmonary fibrosis (IPF) or any chronic lung disease, it’s known that an acute exacerbation, illness or fluke decrease in lung function could drastically change their ability to breathe. Since this can and does happen for unknown reasons, there is often this sense of “living everyday…
There must be a better way! For those of you using supplemental oxygen, you know it is a blessing and a curse. It’s a blessing because without it we would die, but a curse because it is so difficult to access, use, and live with daily. Check out…
As we begin a new year, I want to wish all of you a happy and healthy 2018. I hope the holiday season was magical for you and that the year is off to a great start. Each new year, I like to reflect on the time…
Owlstone Medical is among nine finalists of the IPF Catalyst Challenge to receive $1 million to fund research into idiopathic pulmonary fibrosis (IPF). If it wins, the British company will use the money to promote research into identifying IPF-linked biomarkers in patients’ breath via its proprietary Breath…
